NGM Biopharmaceuticals Inc

NASDAQ:NGMUnited States

NGM Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing novel, potentially life-changing medicines based on scientific understanding of key biological pathways underlying grievous diseases with critical unmet or underserved patient need. The Company’s portfolio of product candidates includes NGM707, NGM831, NGM438, NGM120, NGM621, aldafermin, NGM936 and MK-3655. NGM707 is a dual antagonist monoclonal antibody that is designed to improve patient immune responses to tumors by inhibiting both Immunoglobulin-like transcript 2 (ILT2) and Immunoglobulin-like transcript 4 (ILT4). The Company's NGM831 is an antagonist antibody that is designed to block the interaction of Immunoglobulin-like transcript 3 (ILT3) with fibronectin, as well as other cognate ligands. NGM438 is an antagonist antibody that is designed to inhibit leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) and promote anti-tumor immune responses.

Contact Information

Headquarters

333 Oyster Point BlvdSOUTH SAN FRANCISCO, CA, United States 94080-1978

Phone

650-243-5555

Fax

650-583-1646

Executives

Chairman of the Board

William Rieflin

Chief Executive Officer, Director

David Woodhouse

Chief Financial Officer

Jean - Frederic Viret

Executive Vice President, Chief Medical Officer

Hsiao Lieu

Senior Vice President, Chief Accounting Officer, Chief Compliance Officer, General Counsel, Company Secretary

Valerie Pierce